Outcomes of "Early" Withdrawal of Corticosteroid Sparing Immunomodulatory Therapy for Birdshot Retinochoroidopathy. (3rd October 2019)

• Record Type: Journal Article
• Authors: You, Caiyun; Meese, Halea; Stephenson, Andrew; Montieth, Alyssa; Ma, Lina; Hernandez, Mikhail; Kubaisi, Buraa; Syeda, Sarah; Foster, C. Stephen
• Is Part Of: Ocular immunology and inflammation. Volume 27:Number 7(2019)
• Page Start: 1165
• Page End: 1173
• Publication Date: 2019-10-03
• Subjects: birdshot retinochoroidopathy -- corticosteroid sparing -- immunomodulatory therapy -- ocular inflammation -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2018.1506040
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To review early withdrawal of immunomodulatory therapy (IMT) for birdshot retinochoroidopathy (BSRC). Design : Retrospective case-series of sixteen patients with Human-leukocyte-antigen-A29-positive BSRC treated with IMT ≥ 1 year and discontinued prior to achieving durable remission, observed ≥ 6 months off IMT. Results : Mean duration on IMT was 42.4 months. At discontinuation, quiescence was achieved in 75.0% of eyes. Subjects off IMT for 6 months, 1 year, and 3 years showed quiescence in 75.0%, 77.8%, and 80.0% of eyes. No significantly decreased vision was found 6 or 12 months after discontinuation. One eye experienced significantly decreased vision following 3 years without IMT. Significantly decreased amplitude on electroretinography and worse deviation parameters in perimetry were found in patients 3 years after withdrawal that experienced early discontinuation when compared with those achieving durable remission on IMT > 2 years (p < 0.05). Conclusion : The possibility of electroretinography and perimetry results worsening after early IMT discontinuation remained if the patients couldn't achieve remission.